Source comparison
BPC-157 for GERD: Research Context Comparison
Rat gastric ulcer (cysteamine-induced) 10 mcg/kg IP daily VEGF upregulation, angiogenesis 78% ulcer index reduction at 24h Saline: 31% reduction Strongest preclinical evidence for mucosal repair—mechanism translates to human gastric physiology but dosing extra
This comparison does not assign a generated winner or score.
- Rat gastric ulcer (cysteamine-induced)
- 10 mcg/kg IP daily
- VEGF upregulation, angiogenesis
- 78% ulcer index reduction at 24h
- Saline: 31% reduction
- Strongest preclinical evidence for mucosal repair—mechanism translates to human gastric physiology but dosing extrapolation uncertain
- Rat esophagitis (gastroduodenal reflux model)
- 10 mcg/kg SC daily
- Inflammatory cytokine suppression, epithelial turnover
- 63% erosion score reduction at 14 days
- Omeprazole 20mg/kg: 41% reduction
- Direct head-to-head with PPI shows superior histological healing—suggests tissue repair outperforms acid suppression alone in structural damage
- In vitro gastric epithelial cells (oxidative stress model)
- 1–10 ng/mL culture media
- NO pathway stabilization, ROS scavenging
- 54% increase in cell viability under H2O2 stress
- Untreated: 19% viability
- Demonstrates cytoprotective effect independent of acid exposure—relevant for Barrett's esophagus where cellular oxidative damage persists despite PPI therapy
- Rat duodenal ulcer (chronic NSAID model)
- 10 mg/kg oral daily
- Fibroblast activation, collagen synthesis
- Near-complete healing at 72h vs 40% in controls
- Saline control
- High-dose oral administration effective—suggests gastric juice stability and systemic absorption, though dose scaling to humans unclear